Immunovant (IMVT) Net Equity Issued and Repurchased (2019 - 2025)

Immunovant's Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $450.0 million for Q1 2025.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $450.0 million in Q1 2025, while the trailing twelve-month figure through Mar 2026 was $450.0 million (down 13.54% YoY) and the FY2026 annual result came in at $544.2 million, up 20.93% from the prior year.
• Net Equity Issued and Repurchased was $450.0 million for Q1 2025 at Immunovant, up from $70.5 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $450.0 million in Q1 2025 and bottomed at -$254.0 million in Q1 2021.
• A 3-year average of $116.6 million and a median of $135.2 million in 2021 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 6.33% in 2021, while the deepest fall reached 6.33% in 2021.
• Immunovant's Net Equity Issued and Repurchased stood at $200.0 million in 2021, then tumbled by 64.75% to $70.5 million in 2022, then surged by 538.3% to $450.0 million in 2025.
• Business Quant data shows IMVT's Net Equity Issued and Repurchased at $450.0 million in Q1 2025, $70.5 million in Q4 2022, and $200.0 million in Q3 2021.